Clinical TrialMay 14, 2026, 07:57 AM
Galmed: Aramchol Meglumine (AM) 400mg Increases Bioavailability by ~500%
AI Summary
Galmed Pharmaceuticals announced positive results from its first-in-man Pharmacokinetics Study (AM-001) of oral Aramchol Meglumine (AM). The study showed that 400mg AM increased bioavailability by approximately 500% compared to 300mg Aramchol Free Acid (AA), enabling a transition to a once-daily lower dose. This advancement is expected to solidify IP protection, potentially reduce drug costs by 50%, and improve patient convenience, positioning Aramchol as a valuable tool for GI conditions including MASH and GI cancers.
Key Highlights
- Galmed's 400mg Aramchol Meglumine (AM) increased bioavailability by ~500% compared to 300mg Aramchol Free Acid (AA).
- The study supports a transition to a once-daily lower 400mg dose of AM.
- This development solidifies and prolongs Aramchol's IP protection.
- Potential reduction in drug Cost of Goods Sold (CoGs) by approximately 50%.
- Expected improvement in patient convenience and compliance with the new formulation.
- An additional PK study (AM-003) comparing AM 400mg tablets once daily with AA 300mg tablets twice daily is ongoing.
- Aramchol is being evaluated in pre-clinical studies for GI cancer treatments and MASH.
Price Impact
More from GLMD